|
|
|
|
|
by PaulRobinson
2323 days ago
|
|
I'm not involved in the drug discovery process, but I can imagine that manufacturers would be interested in helping to use AI to deal with the funnel much more effectively to get to those ~5 molecules much more efficiently. You're still left with double-blind trials and having to get large sample groups to try those molecules though. And it's for that reason that drug discovery is always likely to be quite slow, complex and expensive - the efficiency gains will be pushed towards the top of the funnel to make new ideas reasonable to explore, I would imagine. My point was that when you're not dealing with human physiology and instead dealing with problems that are more tractable through AI - i.e. using regression to tune algorithms through patterns in data - you are going to get quicker and more impactful returns without the same complexity. And - critically - it's OK to often trust the AI solution you have without understanding causality. If you later find it's doing something odd that is undesirable, you can use that data to help tune the algorithm again without having to understand the causal relationship. Put another way, you can teach an AI to get better without necessarily understanding the subject completely yourself. |
|